Inactivation of NLRP3 inflammasome by dephosphorylation at Serine 658 alleviates glial inflammation in the mouse model of Parkinson’s disease
These findings position Psoralen as a promising NLRP3 inflammasome inhibitor, offering a potential therapeutic avenue for PD and other NLRP3 inflammasome-related diseases. Additionally, this research highlights the innovative approach of targeting specific phosphorylation sites on the NLRP3 protein to reduce neuroinflammation.
Authors
- Ren-Wen Han (ORCID: https://orcid.org/0009-0003-7069-3236)
- Jingwei Jiang (ORCID: https://orcid.org/0000-0002-9163-3633)
- Yue-Han Chen
- Ming Lu (ORCID: https://orcid.org/0000-0001-8018-8389)
- Yang Liu (ORCID: https://orcid.org/0000-0003-4243-2330)
- Cong Wang (ORCID: https://orcid.org/0000-0003-2626-9596)
- Ting Liu (ORCID: https://orcid.org/0000-0003-1816-5551)
- Rongxin Zhu (ORCID: https://orcid.org/0000-0001-5133-0868)
- Lei Cao (ORCID: https://orcid.org/0009-0001-7548-3866)
- Lei Huang (ORCID: https://orcid.org/0009-0007-7546-1994)
Institutions
- Nanjing University of Chinese Medicine (CN)
- China Pharmaceutical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Molecular Neurodegeneration
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1186/s13024-025-00818-z
- Citations
- 12
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 9.67
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China